Working for customers it could not have served a year ago: the company's deliverable capability just stepped up a class
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否传达公司现在能做一些一年前不能做的事情,并且有真实客户为此付费,且业务仍处于早期阶段。 分析: 1. 关于ICP(ICE-COLD PCR)技术:一年前只有一个肺癌检测,现在有5个panel覆盖17个外显子5个基因,涉及肺癌、结肠癌、黑色素瘤和胰腺癌。这是产品扩展,但这是否是能力跃升?管理层提到与Perkin Elmer的合作,但那是共同营销协议,尚未有收入。管理层估计2019年收入在几十万到几百万美元之间,但这是预测,不是当前付费工作。所以ICP部分没有证明有付费工作。 2. 关于病理服务:收入从上一季度增长近50%,预计到2019年中期每月超过100万美元。但这是增长,不是能力跃升?管理层提到销售团队扩大,但这是增量改进。没有明确对比一年前不能做什么现在能做什么。 3. 关于IV-Cell和HemeScreen:IV-Cell是专有细胞遗传学培养基,之前与宾大合作验证,现在商业化进行中,但未提及有付费客户。HemeScreen刚推出两周,已收到订单,但这是新测试,是否是一年前不能做的?管理层说HemeScreen源于现有测试的缺陷,他们开发了替代品,现在开始商业化。但这是否是能力跃升?可能,但需要看是否有付费工作。管理层说“自推出以来,我们已经收到了许多订单”,但具体数量未明,且这是新测试,可能算早期。但关键是要有对比:一年前他们不能做这个测试吗?他们之前用的是现有测试,现在有了自己的替代品,但这是否是能力跃升?可能算是,但需要看是否明确对比。 4. 关于实验室内部扩展:CFO提到“成功扩展了内部分子检测能力,这将消除对外包的需求”,这暗示之前外包,现在自己做,这是能力提升,但这是否是付费工作?这是内部能力,不是直接客户付费。 综合来看,管理层没有明确说“一年前我们不能做X,现在能做X,并且有客户为此付费”。他们提到产品线扩展、销售增长、新测试推出,但缺乏具体的before/after对比和付费证明。特别是ICP,虽然有Perkin合作,但收入是预测。HemeScreen有订单,但刚推出,且没有明确对比一年前不能做。病理服务增长是增量。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| NGVT | Ingevity Corporation | Q4 2021 | 2022-02-25 | B |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| AEHR | Aehr Test Systems | Q2 2017 | 2017-01-05 | F |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
TGLS · Q2 2023 → YESThe question is about whether management conveys a new capability that they can now do something they couldn't do a year ago, that customers are paying for now, and it's still early. YES Management explicitly contrasts the new capability against the prior limitation: extra capacity now enables them to sell stand-alone architectural glass and aluminum framing products that were previously allocated to window production due to capacity constraints. This is a clear before/after step-change in the class of work they can accept and perform. Real customers are already paying for this new output: the transcript states they have a little bit more installation in stand-alone product sales the rest of the year, and they are now very well positioned to increasingly service large homebuilders’ customers as well as demand for the stand-alone aluminum and glass products, with the absorption of new capacity and ability to offer a wider range of solutions to customers described as positive overall.
TACT · Q4 2022 → YESThe question is: Does management convey that the company CAN NOW ACTUALLY DO SOMETHING that it COULD NOT DO ROUGHLY A YEAR AGO, and that REAL CUSTOMERS ARE ALREADY PAYING FOR THAT NEW CAPABILITY NOW, ...YES The transcript shows management describing a clear before/after step-change in casino and gaming printers: they could produce printers before, but now they have added a third line in Q3 and begun manufacturing on a fourth line in Q4, enabling them to meet demand and take market share that the prior competitor could not supply 12 months ago.
ZVIA · Q1 2022 → YESThe question is: Does management convey that the company CAN NOW ACTUALLY DO SOMETHING that it COULD NOT DO ROUGHLY A YEAR AGO, and that REAL CUSTOMERS ARE ALREADY PAYING FOR THAT NEW CAPABILITY NOW, ...YES Management describes the launch of single-serve 12-ounce cans as a first-time capability: “we began selling Zevia’s soda in single cans for the first time in a 12-ounce sleek format,” now “available cold in several grocery retailers” with “some of which is shipping now.